Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors.

Yi WangJianfen XuMingjun DongKaitai LiuYi LuKe ChenYuepeng CaoHang ShiYanping BeiJianjiong LiJianpei ZhaoYisheng CaoNing LuLu YangHaizhong LiuPing CaiKai LiTong YangNing HeJing DongChen Zhang

Published in: Journal of gastrointestinal oncology (2024)

The real-world efficacy and safety of fruquintinib in advanced CRC patients are numerically superior to that in the previous phase III studies. SMI, brain metastasis and CEA could serve as potential markers for patient selection.

Keyphrases

prognostic factors
phase iii
metastatic colorectal cancer
end stage renal disease
clinical trial
open label
chronic kidney disease
newly diagnosed
ejection fraction
double blind
white matter
randomized controlled trial
cross sectional
study protocol
placebo controlled
patient reported